Home / Pharmaceutical / Global Alzheimer’s Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025

Global Alzheimer’s Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025

Published: Mar 2016 | Published By: Acute Market Research

Global Alzheimer’s Therapeutics Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017 - 2025, the Alzheimer’s therapeutics market was valued at USD 9,892.2 Mn in 2017, and is expected to reach USD 15,361.8 Mn by 2025, expanding at a CAGR of 8.02% from 2017 to 2025.

Market Insights

Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.

Pipeline Analysis

The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.

Key Market Movements:

• Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
• The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
• Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
• In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Alzheimer’s Therapeutics Market Portaiture
2.2 Global Alzheimer’s Therapeutics Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Alzheimer’s Therapeutics Market: Market Dynamics and Outlook
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)

Chapter 4 Global Alzheimer’s Therapeutics Market, By Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Alzheimer’s Therapeutics Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis International AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Axovant Sciences Ltd.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Acadia Pharmaceuticals, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Biotie Therapies
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Astra Zeneca plc
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 F. Hoffman Le Roche
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Merck & Co.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 H. Lundbeck A/S
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 Takeda Pharmaceutical Company Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

TABLE 1 Global Alzheimer’s Therapeutics Market Revenue, by Drugs, 2015 – 2025 (USD Mn)
TABLE 2 Global Alzheimer’s Therapeutics Marrket Revenue, by Geography, 2015 – 2025 (USD Mn)
TABLE 3 North America Alzheimer’s Therapeutics Market Revenue, by Country, 2015 – 2025 (USD Mn)
TABLE 4 Europe Alzheimer’s Therapeutics Market Revenue, by Country, 2015 – 2025 (USD Mn)
TABLE 5 Asia - Pacific Alzheimer’s Therapeutics Market Revenue, by Country, 2015 – 2025 (USD Mn)
TABLE 6 Rest of the World Alzheimer’s Therapeutics Market Revenue, by Region, 2015 – 2025 (USD Mn)

FIG. 1 Global Alzheimer’s Therapeutics Market, by Drugs, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Alzheimer’s Therapeutics Market, 2015
FIG. 4 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
FIG. 5 Global Memantine Hydrochloride Market for Alzheimer’s Treatment, 2015 – 2025 (USD Mn)
FIG. 6 Global Donepezil Hydrochloride Market for Alzheimer’s Treatment, 20137– 2022 (USD Mn
FIG. 7 Global Rivastigmine Market for Alzheimer’s Treatment, 2015 –2025 (USD Mn)
FIG. 8 Global Galantamine Hydrobromide Market for Alzheimer’s Treatment, 2015 – 2025 (USD Mn)
FIG 9 Pipeline Analysis: Global ENA713 Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 10 Pipeline Analysis: Global Flutemetamol (18F) Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global LY450139 Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Dimebon Market for Alzheimer’s Therapeutics, Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Aripiprazole (BMS-337039) Market for Alzheimer's Therapeutics, Upto 2022 (USD Mn)
FIG 14 Global U.S. Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG 15 Global Canada Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG 16 Global U.K Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 17 Global Germany Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 18 Global Rest of Europe Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 19 Global China Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 20 Global Japan Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 21 Global Rest of Asia Pacific Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 22 Global Latin America Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)
FIG. 23 Global Middle East and Africa Alzheimer’s Therapeutics Market Revenue, 2015 – 2025 (USD Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +